The trial also reported dose-dependent increases in heart rate that peaked around 24 weeks and declined [] By Clark Jones, PhD, Velora Research Written and reviewed for scientific accuracy by Clark Jones, PhD ([ORCID 0009-0005-9356-0297]( Last reviewed 2026-05-28
Regarding the cardiovascular outcomes, when examining other individual components of MACE, the analysis showed no significant differences between combination therapy and GLP-1RA monotherapy or SGLT-2i monotherapy in terms of cardiovascular mortality, non-fatal myocardial infarction, stroke, and all-cause mortality (Fig
Medication modification will likely be accompanied by a conversation about lifestyle factors, such as eating and exercise
Yes, with caution
With our medical director, Rafael Olartecoechea, MD, we offer a comprehensive approach to weight management
Interestingly, in both Prx3 and Prx2 we observe that the rate of change of Prx3 or Prx2 activity with respect to the concentration of Prx3 or Prx2 shows a minimum